These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 29264688

  • 1. Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes.
    Cai J, Liu L, Zheng J, Zhang L, Jiang X, Li P, Sha A, Ren J.
    J Assist Reprod Genet; 2018 Mar; 35(3):467-473. PubMed ID: 29264688
    [Abstract] [Full Text] [Related]

  • 2. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
    Melado Vidales L, Fernández-Nistal A, Martínez Fernández V, Verdú Merino V, Bruna Catalán I, Bajo Arenas JM.
    Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E, Tolikas A, Daniilidis A, Asimakopoulos B.
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [Abstract] [Full Text] [Related]

  • 4. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å, Nilsson L, Oleröd G, Thurin-Kjellberg A, Bergh C.
    Hum Reprod; 2017 Apr 01; 32(4):811-819. PubMed ID: 28175316
    [Abstract] [Full Text] [Related]

  • 5. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L, Fernández-Nistal A, Martínez Fernández V, Verdú Merino V, Bruna Catalán I, Bajo Arenas JM.
    Minerva Ginecol; 2017 Apr 01; 69(2):128-134. PubMed ID: 27310675
    [Abstract] [Full Text] [Related]

  • 6. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, Choi YM, Kim JG, Moon SY.
    Fertil Steril; 2008 Apr 01; 89(4):860-7. PubMed ID: 18249372
    [Abstract] [Full Text] [Related]

  • 7. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K, Gelbaya TA, Laing I, Nardo LG.
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun 01; 150(2):166-70. PubMed ID: 20223579
    [Abstract] [Full Text] [Related]

  • 8. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
    Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R.
    Fertil Steril; 2013 May 01; 99(6):1644-53. PubMed ID: 23394782
    [Abstract] [Full Text] [Related]

  • 9. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A, Margalioth EJ, Chetrit AB, Gal M, Goldberg D, Alerhand S, Eldar-Geva T.
    Eur J Obstet Gynecol Reprod Biol; 2014 May 01; 176():163-7. PubMed ID: 24630573
    [Abstract] [Full Text] [Related]

  • 10. Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors.
    Polyzos NP, Stoop D, Blockeel C, Adriaensen P, Platteau P, Anckaert E, Smitz J, Devroey P.
    Reprod Biomed Online; 2012 May 01; 24(5):532-9. PubMed ID: 22417669
    [Abstract] [Full Text] [Related]

  • 11. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.
    Nelson SM, Klein BM, Arce JC.
    Fertil Steril; 2015 Apr 01; 103(4):923-930.e1. PubMed ID: 25624196
    [Abstract] [Full Text] [Related]

  • 12. Comparison of antral follicle count and serum anti Müllerian hormone level for determination of gonadotropin dosing in in-vitro fertilization: randomized trial.
    Li HWR, Ko JKY, Lee VCY, Yung SSF, Lau EYL, Yeung WSB, Ho PC, Ng EHY.
    Ultrasound Obstet Gynecol; 2020 Mar 01; 55(3):303-309. PubMed ID: 31325336
    [Abstract] [Full Text] [Related]

  • 13. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP, Macklon NS, Fauser BC.
    J Clin Endocrinol Metab; 2003 Jan 01; 88(1):166-73. PubMed ID: 12519847
    [Abstract] [Full Text] [Related]

  • 14. Is there a preferred time interval between gonadotropin-releasing hormone (GnRH) agonist trigger and oocyte retrieval in GnRH antagonist cycles? A retrospective cohort of planned fertility preservation cycles.
    Ranit H, Shmuel H, Ahlad A, Shirley G, Meny H, Tal I, Assaf BM, Chana AL, Yaakov B, Efrat EB, Anat HK.
    J Assist Reprod Genet; 2024 Jun 01; 41(6):1531-1538. PubMed ID: 38492156
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients.
    Guo Y, Jiang H, Hu S, Liu S, Li F, Jin L.
    J Ovarian Res; 2021 Aug 28; 14(1):111. PubMed ID: 34454544
    [Abstract] [Full Text] [Related]

  • 16. Retrospective cohort study: AMH is the best ovarian reserve markers in predicting ovarian response but has unfavorable value in predicting clinical pregnancy in GnRH antagonist protocol.
    Xu H, Zeng L, Yang R, Feng Y, Li R, Qiao J.
    Arch Gynecol Obstet; 2017 Mar 28; 295(3):763-770. PubMed ID: 28012077
    [Abstract] [Full Text] [Related]

  • 17. Relationship Between Anti-Müllerian Hormone and In Vitro Fertilization-Embryo Transfer in Clinical Pregnancy.
    Sun XY, Lan YZ, Liu S, Long XP, Mao XG, Liu L.
    Front Endocrinol (Lausanne); 2020 Mar 28; 11():595448. PubMed ID: 33343511
    [Abstract] [Full Text] [Related]

  • 18. Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk.
    Gao R, Liao X, Huang W, Zeng R, Qin L, Bai P.
    Front Endocrinol (Lausanne); 2022 Mar 28; 13():905263. PubMed ID: 35757417
    [Abstract] [Full Text] [Related]

  • 19. What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?
    Knez J, Kovačič B, Medved M, Vlaisavljević V.
    Reprod Biol Endocrinol; 2015 Jun 10; 13():58. PubMed ID: 26059906
    [Abstract] [Full Text] [Related]

  • 20. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.
    Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC.
    Hum Reprod; 2012 Jun 10; 27(6):1829-39. PubMed ID: 22473395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.